Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.
125 Summer Street
Boston, Massachusetts 02110
Phone: 17818487100
www.haemonetics.com
No summary available.
No summary available.
Financial release accessible online BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a…
BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, …
BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and the first commercial European procedures for the…
Haemonetics'' SavvyWire® guidewire receives CE Mark, revolutionizing TAVI procedures. First European use in France and Netherlands showcases improved efficiency and patient outcomes. Learn about this groundbreaking 3-in-1 solution.
Haemonetics (NYSE: HAE ) is scheduled to report first-quarter fiscal 2025 results on Aug 8, before market open. Earnings Surprise History HAE has a strong earnings surprise history. It beat on earnings in each of the trailing four quarters, the average surprise being 13.24%. In the last reported quarter, the company''s adjusted earnings per share of 90 cents surpassed the Zacks Consensus Estimate by 2.27%. Q1 Estimates The Zacks Consensus Estimate for revenues is pegged at $335.9 million, suggesting an increase of 7.9% from the year-ago reported figure. The Zacks Consensus Estimate for EPS of $1.03 indicates a year-over-year decline of 1.9%. Estimate Revision Trend Ahead of Earnings Estimates for first-quarter earnings have remained constant at $1.03 per share in the past 30 days. Let''s take a look at how things might have shaped up for the MedTech major prior to the announcement. Factors at Play In the fiscal first quarter, Haemonetics'' Hospital business segment''s recurring revenues are expected to have maintained the trend of robust organic gains, contributing significantly to the company''s overall revenue growth.
No summary available.
Haemonetics launches VASCADE MVP XL targeting $2.7B vascular market. FDA approved, first success by Dr. McElderry. Enhanced closure capabilities, full release soon.
BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP XL mid-bore venous closure device. The…